65,437 trials
Glaucoma · Macular Degeneration · Glaucoma Suspect
Primary: Visual Impairment Measured by Visual Functioning Test — 80.6; 74.2; 81.1 score on a scale — p=0.011
Chronic Kidney Diseases · Hypertension
Primary: Change in Systolic Blood Pressure (SBP) From Baseline to 180 Days — 14.6; 11.7 mmHg
Recurrent Neuroendocrine Tumor · Metastatic Neuroendocrine Tumor
Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants
Healthy Participants
Primary: Rates of Hepatic Mitochondrial Oxidation — 262; 149 micromol/min
Cystic Fibrosis
Primary: Absolute Change in FEV1 % Predicted From Week 0 to Week 6 — 0.2; -0.2 FEV1 % predicted — p=<0.0001
Alcohol Use Disorder
Primary: The Primary Outcome Measure Will be Percent Days of Abstinence (PDA) by Week — 73.29; 66.96; 88.20; 79.59 percentage of days abstinent per week — p=0.30
Pulmonary Hypertension
Primary: Calculated Pulmonary Vascular Resistance (PVR) — 7.97; 8.23; 7.27; 7.11 Wood units (WU) — p=0.541
Post COVID-19 Syndrome
Primary: Changes From Baseline in Visual Analog Scale of Neurological Symptoms. - Extreme Fatigue (ANCOVA Model) — -2.376; -2.430 score on a scale (10 points total) — p=0.9416
Obesity
Primary: Mean Number of Uses of the Temptation Tracker — 9.5 uses of this mobile app feature
Total Shoulder Arthroplasty
Primary: Pain Score in the 24 Hours After Surgery — 0.76; 3.37 score on a scale
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection · COVID-19 · Long COVID
Primary: Daily Diary Pain NRS — -2.2; -2.0 units on a scale
Surgical Stomas
Primary: Leakage Through Coupling Registered at Each Bag Change (Yes/no) — 0.151; 0.237 Proportion of bag changes/participant — p=0.164
Measure Accuracy of Respiratory Rate
Primary: Accuracy of Device Under Test for the Measurement of Respiratory Rate, Measured in Breath/Min — 2.9 breaths/min
Alcohol Abuse · Cognitive Deficit in Attention
Primary: Participant Retention — 85.71; 88.89 percentage of participants
Chronic Pain
Primary: Opioid Use — -6.7; -8.0 MME — p=.89